We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Jabil (JBL) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Jabil (JBL - Free Report) is set to report first-quarter fiscal 2020 results on Dec 17.
For first-quarter fiscal 2020, Jabil expects total revenues between $6.65 billion and $7.35 billion.
Diversified Manufacturing Services (DMS) revenues are forecast to be $3.1 billion, up roughly 3% year over year. Electronics Manufacturing Services (EMS) revenues are forecast to be $3.9 billion, up nearly 11% year over year.
Moreover, the company’s core earnings are expected between 82 cents and $1.04 per share on a non-GAAP basis.
The Zacks Consensus Estimate for earnings stayed at 94 cents over the past 30 days. The consensus mark for revenues is pegged at $6.96 billion, indicating growth of 6.93% from the year-ago quarter’s reported figure.
In fourth-quarter fiscal 2019, the company reported adjusted earnings of 88 cents per share, which beat the Zacks Consensus Estimate by a couple of cents and improved 25.7% year over year.
Revenues increased 13.9% year over year to $6.57 billion, which was within management’s guided range of $6.3-$6.9 billion. However, the figure lagged the Zacks Consensus Estimate of $6.61 billion.
Notably, the company’s earnings beat the Zacks Consensus Estimate in the trailing four quarters, the average positive surprise being 3.73%.
Let’s see how things have shaped up for this announcement.
Jabil’s fiscal first-quarter results are expected to have benefited from contract wins in healthcare, automotive, cloud and 5G. Moreover, improving end-market diversification is expected to have been a key catalyst.
The DMS segment is likely to have benefited from an improved business mix, driven by Jabil’s impressive diversification efforts. EMS growth is expected to have been driven by new business wins in 5G wireless, cloud and automotive end markets.
However, performance of Jabil’s DMS segment is expected to have suffered due to a soft mobility business and sluggish spending in the semiconductor capital equipment business. Moreover, increasing competition in the industry is expected to have weighed on margins.
Key Developments in Q1
Eguana announced that it has inked a multi-year master supply agreement with Jabil to manufacture its residential and commercial energy storage systems. Jabil will initially focus on QCELLS Enduro production.
What Our Model Says
According to the Zacks model, the right combination of two key ingredients — a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — increases the odds of a positive earnings surprise.
Jabil has an Earnings ESP of 0.00% and a Zacks Rank #3, which makes surprise prediction difficult. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable Combination
Here are some stocks you may consider, as according to our proven model, these have the right mix of elements to beat estimates this time around.
Pfizer Inc. (PFE - Free Report) currently has an Earnings ESP of +1.75% and a Zacks Rank of 2.
Cloudera, Inc. has an Earnings ESP of +4.55% and a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Jabil (JBL) to Report Q1 Earnings: What's in the Cards?
Jabil (JBL - Free Report) is set to report first-quarter fiscal 2020 results on Dec 17.
For first-quarter fiscal 2020, Jabil expects total revenues between $6.65 billion and $7.35 billion.
Diversified Manufacturing Services (DMS) revenues are forecast to be $3.1 billion, up roughly 3% year over year. Electronics Manufacturing Services (EMS) revenues are forecast to be $3.9 billion, up nearly 11% year over year.
Moreover, the company’s core earnings are expected between 82 cents and $1.04 per share on a non-GAAP basis.
The Zacks Consensus Estimate for earnings stayed at 94 cents over the past 30 days. The consensus mark for revenues is pegged at $6.96 billion, indicating growth of 6.93% from the year-ago quarter’s reported figure.
In fourth-quarter fiscal 2019, the company reported adjusted earnings of 88 cents per share, which beat the Zacks Consensus Estimate by a couple of cents and improved 25.7% year over year.
Revenues increased 13.9% year over year to $6.57 billion, which was within management’s guided range of $6.3-$6.9 billion. However, the figure lagged the Zacks Consensus Estimate of $6.61 billion.
Notably, the company’s earnings beat the Zacks Consensus Estimate in the trailing four quarters, the average positive surprise being 3.73%.
Let’s see how things have shaped up for this announcement.
Jabil, Inc. Price and EPS Surprise
Jabil, Inc. price-eps-surprise | Jabil, Inc. Quote
Factors to Watch
Jabil’s fiscal first-quarter results are expected to have benefited from contract wins in healthcare, automotive, cloud and 5G. Moreover, improving end-market diversification is expected to have been a key catalyst.
The DMS segment is likely to have benefited from an improved business mix, driven by Jabil’s impressive diversification efforts. EMS growth is expected to have been driven by new business wins in 5G wireless, cloud and automotive end markets.
However, performance of Jabil’s DMS segment is expected to have suffered due to a soft mobility business and sluggish spending in the semiconductor capital equipment business. Moreover, increasing competition in the industry is expected to have weighed on margins.
Key Developments in Q1
Eguana announced that it has inked a multi-year master supply agreement with Jabil to manufacture its residential and commercial energy storage systems. Jabil will initially focus on QCELLS Enduro production.
What Our Model Says
According to the Zacks model, the right combination of two key ingredients — a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — increases the odds of a positive earnings surprise.
Jabil has an Earnings ESP of 0.00% and a Zacks Rank #3, which makes surprise prediction difficult. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable Combination
Here are some stocks you may consider, as according to our proven model, these have the right mix of elements to beat estimates this time around.
Perficient, Inc. (PRFT - Free Report) presently has an Earnings ESP of +2.17% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Pfizer Inc. (PFE - Free Report) currently has an Earnings ESP of +1.75% and a Zacks Rank of 2.
Cloudera, Inc. has an Earnings ESP of +4.55% and a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>